GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr

September 22, 2022

https://www.globenewswire.com/news-release/2022/09/22/2520704/0/en/GSK-and-Spero-Therapeutics-Announce-Exclusive-License-Agreement-for-Late-Stage-Antibiotic-Asset-Tebipenem-HBr.html

The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian countries

Spero Therapeutics receives $66 million upfront, with potential for future milestone payments, and tiered royalties.

Read more at globenewswire.com

Related news for (SPRO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.